136 related articles for article (PubMed ID: 15205592)
1. 807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Escaned J; Moreno R; Hernández-Antolin R; Sabaté M; Trabetti E; Pignatti PF; Macaya C
Blood Coagul Fibrinolysis; 2004 Jul; 15(5):427-33. PubMed ID: 15205592
[TBL] [Abstract][Full Text] [Related]
2. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
Am J Cardiol; 2005 Oct; 96(8):1095-9. PubMed ID: 16214444
[TBL] [Abstract][Full Text] [Related]
3. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Alfonso F; Sabaté M; Fernández C; Stranieri C; Trabetti E; Pignatti PF; Macaya C
Blood Coagul Fibrinolysis; 2004 Jan; 15(1):89-93. PubMed ID: 15166949
[TBL] [Abstract][Full Text] [Related]
4. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Hernández-Antolín R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Macaya C
J Invasive Cardiol; 2004 Jun; 16(6):325-9. PubMed ID: 15156004
[TBL] [Abstract][Full Text] [Related]
5. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
[TBL] [Abstract][Full Text] [Related]
6. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Barrera-Ramirez C; Sabaté M; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
Thromb Res; 2005; 115(1-2):101-8. PubMed ID: 15567460
[TBL] [Abstract][Full Text] [Related]
7. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.
Gurbel PA; Cummings CC; Bell CR; Alford AB; Meister AF; Serebruany VL;
Am Heart J; 2003 Feb; 145(2):239-47. PubMed ID: 12595840
[TBL] [Abstract][Full Text] [Related]
8. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose.
von Beckerath N; von Beckerath O; Koch W; Eichinger M; Schömig A; Kastrati A
Blood Coagul Fibrinolysis; 2005 Apr; 16(3):199-204. PubMed ID: 15795539
[TBL] [Abstract][Full Text] [Related]
9. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
[TBL] [Abstract][Full Text] [Related]
10. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.
Hochholzer W; Trenk D; Fromm MF; Valina CM; Stratz C; Bestehorn HP; Büttner HJ; Neumann FJ
J Am Coll Cardiol; 2010 Jun; 55(22):2427-34. PubMed ID: 20510210
[TBL] [Abstract][Full Text] [Related]
11. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Parodi G; Marcucci R; Valenti R; Gori AM; Migliorini A; Giusti B; Buonamici P; Gensini GF; Abbate R; Antoniucci D
JAMA; 2011 Sep; 306(11):1215-23. PubMed ID: 21934054
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.
Gladding P; White H; Voss J; Ormiston J; Stewart J; Ruygrok P; Bvaldivia B; Baak R; White C; Webster M
JACC Cardiovasc Interv; 2009 Nov; 2(11):1095-101. PubMed ID: 19926050
[TBL] [Abstract][Full Text] [Related]
13. Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment.
Giusti B; Gori AM; Marcucci R; Sestini I; Saracini C; Paniccia R; Poli S; Giglioli C; Valente S; Prisco D; Gensini GF; Abbate R
Atherosclerosis; 2008 Jan; 196(1):341-348. PubMed ID: 17157856
[TBL] [Abstract][Full Text] [Related]
14. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Verdoia M; Daffara V; Pergolini P; Rolla R; Marino P; Bellomo G; Carriero A; De Luca G;
Vascul Pharmacol; 2017 Aug; 93-95():42-47. PubMed ID: 28433569
[TBL] [Abstract][Full Text] [Related]
16. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome.
Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Romero-Barra M; Camoin L; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
Thromb Haemost; 2007 Feb; 97(2):212-7. PubMed ID: 17264949
[TBL] [Abstract][Full Text] [Related]
17. The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy.
Tatarunas V; Jankauskiene L; Kupstyte N; Skipskis V; Gustiene O; Grybauskas P; Lesauskaite V
Blood Coagul Fibrinolysis; 2014 Jun; 25(4):369-74. PubMed ID: 24418943
[TBL] [Abstract][Full Text] [Related]
18. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?
Angiolillo DJ; Fernández-Ortiz A; Bernardo E; Barrera Ramírez C; Sabaté M; Fernandez C; Hernández-Antolín R; Escaned J; Alfonso F; Macaya C
J Invasive Cardiol; 2004 Apr; 16(4):169-74. PubMed ID: 15152138
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet effect of 50-mg maintenance dose of clopidogrel compared to 200 mg ticlopidine: a preliminary study.
Fukushima K; Kobayashi Y; Kitahara H; Iwata Y; Kuroda N; Ooyama M; Kuwabara Y; Nomura F; Komuro I
Heart Vessels; 2010 Jan; 25(1):41-4. PubMed ID: 20091397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
